First Wave BioPharma Profit Margin

The latest profit margin for FWBI is -4961.87% as of June 2026. That compares with 15083.24% in the prior-year period — down 132.9% year over year. That is below the Healthcare sector average of 13.39%. Investors often review this figure alongside First Wave BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, FWBI's profit margin moved from 15083.24% to -4961.87% — a 132.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in First Wave BioPharma's valuation or profitability profile.

Against Healthcare companies, FWBI currently prints -4961.87% for profit margin, while the sector average sits near 13.39%. That is roughly 37167.6% below the sector mean. Large gaps often invite a closer look at First Wave BioPharma's growth, margins, and balance sheet.

Profit Margin shows how effectively First Wave BioPharma converts resources into returns. At -4961.87%, FWBI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 15083.24% in the prior-year period — down 132.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting FWBI's profit margin (-4961.87%), review year-over-year change from 15083.24%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.